Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna, Inc.

Moderna Therapeutics - Messenger RNA Therapeutics

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.”

Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.

Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.

We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. 

To learn more, visit www.modernatx.com.

This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products.  We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).

Moderna

August is National Immunization Awareness Month! What is #immunization? What is the difference between immunization and #vaccination? Watch the video to learn more 👇🏽

#NIAM #VaccinesWork

Today, we're reporting financial results and providing business updates for the second quarter of 2023. 

Read more: https://lnkd.in/eQX8mPrC

Each person’s #cancer is different, which is why it can be difficult to treat. Hear more from Cleo Constantine Abram about how we’re researching an individualized treatment approach specific to each person's #tumor, with the goal of training their immune system to fight back.

Happy #RNAday! Today, we celebrate the RNA, one of the most versatile biomolecules we have seen come to life. Because of RNA, we have mRNA - and one strand of #mRNA could change how we stand up to multiple diseases – from the widespread to the extremely rare! 🧬🔬

As we continue to build our company, we are committed to accelerating the next generation of leaders - and our co-op program is a powerful example of how we are building the future of Moderna.
 
This spring, we welcomed one of our largest and most diverse cohorts ever – 100 students from 43 schools, with 69% women and 75% from underrepresented groups.
 
Meet and hear from a few of our spring co-ops as they reflect on their experience, in this latest blog from Tracey Franklin, our Chief Human Resources Officer: https://lnkd.in/eYgAc64Q

#CampusRecruiting #CoOp #TeamModerna

#mRNA can potentially change how we fight and prevent diseases. Hear more from Cleo Constantine Abram about the years of work #scientists have done to help us understand what mRNA is and how it can help teach the body to fight back against #diseases. ⬇

Moderna and Merck announced today the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating mRNA-4257 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) #melanoma.
 
Global recruitment in V940-001 has begun, and the first patients are now enrolling in Australia.
 
Read more: https://lnkd.in/eZTgaFJW

We are proud to be recognized by The Boston Business Journal as one of the most charitable companies in Massachusetts in 2023!

We are honored to receive this recognition and, more importantly, to be able to support local #nonprofit organizations that do incredible work in our communities. Caring deeply about and giving back to the communities where we live and work is an integral part of who we are and what we do.

#ModernaGivesBack #BBJCCA

https://lnkd.in/g4wzCt9A

This week we conducted an onboarding session for our largest cohort of co-ops to date - 122 students!

During onboarding, our latest cohort had the opportunity to put the Moderna #mindsets into practice, learn about employee resource groups and hear from company leaders.

Our co-ops, who represent 26 unique schools, are contributing to impactful projects across all functions at Moderna through mid-December. Join us in welcoming them!

#CampusRecruiting #CoOp #TeamModerna

We're excited to share that Rose Loughlin, our Senior Vice President of Research and Early Development, has been recognized by Endpoints News as one of 20 extraordinary women worldwide who are reshaping #biopharma.
 
Rose joined Moderna nearly 8 years ago, and is responsible for platform research, therapeutics discovery (#cancer, rare diseases, #autoimmune), and non-clinical development.
 
Congratulations, Rose! We look forward to seeing how you and your teams can continue to deliver the greatest possible impact to people through #mRNA #medicines.
 
https://lnkd.in/eMbb4TAj

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	101.54M -	176.97M 74.30%	122.51M 30.77%	48.04M 60.79%	274.49M 471.43%	17.74B 6,361.44%	19.26B 8.61%	6.75B 64.94%
cost of revenue			-12.56M -		7.93M -	2.62B 32,888.78%	5.42B 106.95%	4.69B 13.35%
gross profit	101.54M -	176.97M 74.30%	135.07M 23.68%	48.04M 64.44%	266.56M 454.91%	15.12B 5,571.96%	13.85B 8.41%	2.06B 85.12%
selling and marketing expenses
general and administrative expenses	57.45M -	64.72M 12.66%	94.25M 45.63%	109.62M 16.31%
selling general and administrative expenses	57.45M -	64.72M 12.66%	94.25M 45.63%	109.62M 16.31%	188.27M 71.75%	567M 201.17%	1.13B 99.65%	1.55B 36.84%
research and development expenses	274.72M -	410.46M 49.41%	454.08M 10.63%	496.31M 9.30%	1.37B 176.11%	1.99B 45.29%	3.29B 65.49%	4.84B 47.04%
other expenses	-2.71M -	-1.88M 30.79%	1.83M 197.87%	-12.17M 763.38%	-528.90M 4,244.90%	-735M 38.97%	-45M 93.88%	-14M 68.89%
cost and expenses	325.31M -	446.33M 37.20%	535.78M 20.04%	593.76M 10.82%	1.04B 74.76%	4.44B 327.90%	9.84B 121.69%	10.99B 11.68%
operating expenses	325.31M -	446.33M 37.20%	535.78M 20.04%	593.76M 10.82%	1.03B 73.42%	1.82B 77.04%	4.43B 142.84%	6.30B 42.31%
interest expense				6.61M -	9.89M 49.52%	18M 82.08%	29M 61.11%	38M 31.03%
ebitda	-208.66M -	-248.82M 19.25%	-413.27M 66.09%	-545.72M 32.05%	-763.14M 39.84%	13.30B 1,842.27%	9.77B 26.53%	-3.21B 132.87%
operating income	-223.77M -	-269.36M 20.37%	-413.27M 53.43%	-545.72M 32.05%	-763.14M 39.84%	13.30B 1,842.27%	9.42B 29.15%	-4.24B 145%
depreciation and amortization	15.11M -	20.54M 35.88%	24.86M 21.06%	31.02M 24.77%	31.25M 0.74%	232M 642.38%	348M 50%	621M 78.45%
total other income expenses net	-2.71M -	-1.88M 30.79%	1.83M 197.87%	31.00M 1,589.59%	18.63M 39.91%	-11M 159.04%	155M 1,509.09%	-86M 155.48%
income before tax	-215.17M -	-256.00M 18.97%	-384.41M 50.16%	-514.72M 33.90%	-744.51M 44.65%	13.29B 1,884.39%	9.57B 27.93%	-3.94B 141.17%
income tax expense	1.04M -	-80K 107.67%	326K 507.50%	-695K 313.19%	2.55M 467.05%	1.08B 42,353.94%	1.21B 12.00%	772M 36.36%
net income	-216.21M -	-255.92M 18.36%	-384.73M 50.34%	-514.02M 33.60%	-747.06M 45.34%	12.20B 1,733.33%	8.36B 31.47%	-4.71B 156.37%
weighted average shs out	376M -	376M 0%	81.11M 78.43%	331M 308.07%	381M 15.11%	403M 5.77%	394M 2.23%	382M 3.05%
weighted average shs out dil	376M -	376M 0%	81.11M 78.43%	331M 308.07%	381M 15.11%	431M 13.12%	416M 3.48%	382M 8.17%
eps	-0.58 -	-0.68 17.24%	-4.74 597.06%	-1.55 67.30%	-1.96 26.45%	30.31 1,646.43%	21.26 29.86%	-12.34 158.04%
epsdiluted	-0.58 -	-0.68 17.24%	-4.74 597.06%	-1.55 67.30%	-1.96 26.45%	28.29 1,543.37%	20.12 28.88%	-12.34 161.33%

COM:MODERNATX

Moderna Inc.

Last Close

38.25

22/11 21:00

Market Cap

15.16B

Beta: -

Volume Today

13.33M

Avg: -

Preview